Supplemental Financial Information

9 Months Ended

Sep. 30, 2025

Supplemental Financial Information [Abstract]

Tempus agreement

In November 2023, Recursion entered into a five-year agreement (the Tempus Agreement) with Tempus AI, Inc. (“Tempus”) to purchase access to their records of patient-centric multimodal oncology data and use rights for therapeutic development purposes. This data will be used to improve the training of Recursion’s artificial intelligence and machine learning models and is expected to accelerate Recursion’s drug discovery process. Recursion is making annual payments, ranging between $22.0 million and $42.0 million, up to $160.0 million in aggregate, to Tempus in cash or equity at the Company’s option. The equity value is determined by using the seven-trading day period dollar volume-weighted average price (VWAP) for Recursion Class A common stock ending on the day immediately preceding the date that is five business days prior to the payment date.

Recursion is expensing the record purchases based on a contractually agreed price as “Research and Development” expenses in the Condensed Consolidated Statements of Operations as the records are downloaded. To the extent that the Recursion payments to Tempus are greater than or less than the records purchased amount, Recursion records the applicable amount to “Prepaid data assets” or “Accrued data liability” on the Condensed Consolidated Balance Sheet, respectively. The expense for the record purchases was $49.9 million and $2.9 million for the nine months ended September 30, 2025 and 2024. There was no expense recorded for the three months ended September 30, 2025 and 2024.

Accrued Expenses and Other Liabilities


	September 30,		December 31,
(in thousands)	2025		2024
Accrued compensation	$	24,056	$	50,853
Accrued development expenses	2,497		5,812
Accrued early discovery expenses	7,840		3,095
Accrued professional fees	1,956		787

Materials received not invoiced	1,206		1,590
Accrued license fees	3,000		3,000
Accrued other expenses	12,547		16,735
Accrued expense and other liabilities	$	53,102	$	81,872

Restructuring

In June 2025, Recursion announced a reduction in personnel program to help streamline the Company's operating strategy and post-integration efficiencies. These changes resulted in a workforce reduction of approximately 20%. The Company estimates that it will incur approximately $9.5 million in charges for the workforce reduction, consisting of severance payments and employee benefits. Recursion expects to incur all of these expenses in the year ending December 31, 2025. Recursion records these costs in “General and Administrative” on the Condensed Consolidated Statement of Operations as incurred. The following summarizes the activity related to these restructuring actions and the related accrual as of September 30, 2025:


(in thousands)
Balance as of December 31, 2024	$	—
Expense	8,516
Payments	(7,717)
Balance as of September 30, 2025	$	799

Interest Income, Net


	Three months ended September 30,				Nine months ended September 30,
(in thousands)	2025		2024		2025		2024
Interest income	$	5,540	$	3,826	$	16,541	$	11,138
Interest expense	(833)		(553)		(1,821)		(967)
Interest income, net	$	4,707	$	3,273	$	14,720	$	10,171

For the three and nine months ended September 30, 2025 and 2024, interest income primarily related to earnings on cash and cash equivalents in money market funds. Interest expense primarily related to the Company’s supercomputer financing lease. Interest income, net was included in “Other income (loss), net” on the Condensed Consolidated Statements of Operations.